New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2013
09:13 EDTPCYCPharmacyclics price target raised to $165 from $110 at Wedbush
Wedbush raised its price target to $165 for Pharmacyclics on expectations breakthrough designation in MCL will lead to an earlier than expected approval for ibrutinib. The firm also expects significant off-label use of ibrutinib across hematological malignancies and keeps an Outperform rating on shares of Pharmacyclics.
News For PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PCYC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use